2015 Fiscal Year Final Research Report
Prevention of CRPC and application for docetaxel treatment using flavonoids
| Project/Area Number |
25462472
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IZUMI Kouji 金沢大学, 医学系, 特任助教 (80646787)
KONAKA Hiroyuki 金沢大学, 大学病院, 講師 (40334768)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 前立腺癌 / 2’-hydroxyflavanone / 誘導体 / AR-V7 |
|---|
| Outline of Final Research Achievements |
After progression of CRPC during hormonal treatment and docetaxel treatment, we face difficulty of these treatments. Therefore, it is important to develop new medicines next to taxanes. Then we focused on one of flavonoids, 2’-hydroxyflavanone (2’-HF). 2’-HF inhibited not only cell proliferation of androgen-sensitive prostate cancer LNCaP but also androgen-independent prostate cancer cells PC-3 and DU145. We also examined effect of 2’-HF on androgen receptor (AR) activity. When LNCaP cells transfected with PSA promoter-driven luciferase reporter were treated with 2’-HF in the presence of androgen, AR activity was reduced by 2’-HF. These data indicate that 2’-HF is candidate to treat CRPC after docetaxel treatment.
|
| Free Research Field |
腫瘍学
|
